10.4 Antimicrobial Use and Infection in the Immunosuppressed
Key Takeaways
- Stewardship in the neuro ICU means cultures that do not delay needed drugs, meningitis-range dosing, de-escalation when identities return, and stopping extra coverage that never reached CSF.
- Ceftriaxone and cefepime (and meropenem) are used for meningitis because they reach CSF; piperacillin-tazobactam is not a meningitis drug.
- Empiric community bacterial meningitis is vancomycin plus a third-generation cephalosporin pending cultures; add ampicillin when Listeria risk is present, and add acyclovir when HSV encephalitis is plausible.
- Neutropenia, high-dose steroids, transplant, and CAR-T reopen aspergillus, Pneumocystis, CMV, and cryptococcus; prophylaxis and early antigen or PCR testing beat late cover-everything cocktails.
- Cefepime neurotoxicity—myoclonus, encephalopathy, nonconvulsive status—clusters with unadjusted doses in AKI; obtain EEG and stop cefepime rather than stacking more antiseizure drugs around an ongoing toxin.
An antibiotic that never reaches CSF is theater. This independent OpenExamPrep section covers stewardship in a unit full of EVDs, blood–brain barrier (BBB) penetration, empiric community meningitis (vancomycin plus a third-generation cephalosporin), HSV acyclovir, opportunistic infection in neutropenia, steroids, transplant, and chimeric antigen receptor T-cell (CAR-T) therapy, and how cefepime neurotoxicity mimics nonconvulsive status epilepticus (NCSE). Infectious Diseases Society of America (IDSA) bacterial meningitis and 2017 healthcare-associated ventriculitis documents are the named dosing logic; this chapter teaches that logic for the exam rather than reprinting those PDFs.
Stewardship that still respects a dying brain
Stewardship is not delayed care. It is:
- Right source (CSF, blood, urine, lungs, hardware) without a 45-minute treasure hunt in shock
- Right dose for the compartment (meningitis grams, not pneumonia grams)
- De-escalation when the organism and MIC return
- Duration that matches the disease (ventriculitis is not a 3-day cystitis)
- Stopping drugs that cannot do the job you assigned (piperacillin-tazobactam for meningitis; linezolid as a lone pneumococcal meningitis drug without expert backup)
Every extra day of meropenem selects resistant Gram-negatives and Clostridioides difficile. Every underdose of ceftriaxone in meningitis selects dead patients. Those are both stewardship failures.
BBB penetration: who actually treats meningitis
Inflamed meninges open the barrier somewhat; you still need agents with a track record in CSF.
| Agent | CSF usefulness in meningitis | Exam use |
|---|---|---|
| Ceftriaxone or cefotaxime | Reliable for susceptible pneumococcus and meningococcus at meningitis doses (ceftriaxone 2 g IV every 12 hours in adults) | Community Gram-positive/negative coverage backbone |
| Cefepime | Reaches CSF; anti-pseudomonal | Healthcare ventriculitis; 2 g IV every 8 hours typical adult meningitis dosing |
| Ceftazidime | CSF-active anti-pseudomonal | Alternative to cefepime for healthcare Gram-negatives |
| Meropenem | CSF-active carbapenem | Healthcare ventriculitis, ESBL, or penicillin-allergic pathways; 2 g IV every 8 hours often used for CNS infection |
| Vancomycin | Variable, concentration-dependent; never monotherapy for pneumococcus | Add for resistant pneumococcus until MIC is known; trough commonly 15–20 µg/mL if intermittently dosed |
| Ampicillin | Needs high, frequent dosing (2 g IV every 4 hours) | Listeria |
| Piperacillin-tazobactam | Unreliable CSF levels | Hospital pneumonia or belly—not meningitis |
| Aminoglycosides | Poor CSF after IV dosing | Sometimes adjunct or intraventricular in selected Gram-negatives |
| Acyclovir | Reaches CSF | HSV/VZV |
The classic wrong answer is “broaden to piperacillin-tazobactam” when an EVD patient spikes a fever. You have broadened the abdomen and abandoned the ventricle.
Empiric community meningitis pending cultures
Adult community bacterial meningitis empiric therapy remains vancomycin plus a third-generation cephalosporin (ceftriaxone or cefotaxime) until pneumococcal susceptibility is known. Add ampicillin if the patient is older than about 50 years or immunocompromised (Listeria). Give dexamethasone just before or with the first antibacterial dose when pneumococcus is likely, then stop steroids if a different organism is identified. Do not withhold the first antibacterial hour to wait for LP if LP will be delayed by CT; draw blood cultures and treat, then sample CSF as soon as it is safe.
Healthcare-associated ventriculitis and meningitis (IDSA 2017): vancomycin plus cefepime, ceftazidime, or meropenem, chosen with local Gram-negative resistance in mind. Intraventricular antibiotics are a second-line adjunct when CSF is not clearing, not the opening move in every cloudy EVD.
HSV: acyclovir while the PCR is pending
Fever, altered mental status, seizures, temporal-lobe imaging, or a hemorrhagic CSF profile can be herpes simplex virus (HSV) encephalitis. Start acyclovir 10 mg/kg ideal body weight IV every 8 hours as soon as that phenotype is on the list. Reduce the interval or dose in AKI; acyclovir crystal nephropathy is a real reason creatinine climbs if the patient is volume-down. Stop acyclovir if a sensitive CSF PCR is negative and the story has moved on; do not run 21 days “just in case” without a diagnosis. VZV gets the same drug at similar intravenous doses when shingles plus vasculitis or encephalitis is the concern.
Opportunistic infection: four host stories
Think in hosts, not in random fungus names.
| Host | Window | What to worry about | First moves | |---|---|---| | Neutropenia (especially prolonged, after chemotherapy) | Days of ANC <500/µL | Bacterial Gram-negatives including Pseudomonas; Candida; Aspergillus as days stack | Fever plus neutropenia protocols; chest CT if respiratory symptoms; galactomannan/beta-D-glucan as adjuncts | | High-dose steroids (brain tumor, vasculitis, spinal cord protocols) | Weeks | Pneumocystis jirovecii (PCP), aspergillus, Cryptococcus, Listeria, nocardia, HSV/VZV | PCP prophylaxis with trimethoprim-sulfamethoxazole when steroids are high and prolonged; cryptococcal antigen if headache or encephalopathy | | Solid-organ or allogeneic transplant | Calendar of immune suppression | CMV, PCP, aspergillus, cryptococcus, later JC virus | CMV PCR when leukopenia or colitis or retinitis; continue PCP prophylaxis | | CAR-T | Neutropenic phase, then steroids/tocilizumab for CRS/ICANS | Bacterial sepsis, CMV, aspergillus, PCP if prophylaxis lapses | Do not attribute every encephalopathy to ICANS without considering infection and cefepime |
Aspergillus loves prolonged neutropenia, steroids, and transplant lungs and sinuses. A new nodule, halo sign, or invasive sinus disease is a CT and antifungal decision, not a “watch overnight.” Voriconazole or other mold-active therapy is a named treatment family; check drug interactions with antiseizure meds (phenytoin induces azole metabolism; voriconazole can raise other levels).
PCP presents with hypoxia out of proportion to the chest film, elevated A-a gradient, and sometimes a normal auscultation. Steroid-taper periods are classic. Treatment is high-dose trimethoprim-sulfamethoxazole; add steroids when hypoxemia is significant, following HIV-era logic that is often extended to non-HIV immunocompromised hosts. Prophylaxis is easier than a 14-day ICU stay.
CMV is a transplant and CAR-T virus: fever, marrow suppression, pneumonitis, colitis, retinitis, and occasionally encephalitis. Plasma PCR plus tissue or quantitative CSF PCR when the CNS is involved. Ganciclovir or valganciclovir are the usual first agents; marrow toxicity matters in a patient who is already neutropenic.
Cryptococcus is steroids, transplant, and sometimes unexplained subacute meningitis with high opening pressure. Serum and CSF cryptococcal antigen, India ink as a historical adjunct, and careful pressure management (repeat LPs) are the exam cluster. Amphotericin plus flucytosine induction is the severe-disease backbone; fluconazole consolidates. A positive antigen in an immunocompromised headache is not “colonization.”
CAR-T cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are not infections, but their treatment (tocilizumab, high-dose steroids) plus neutropenia creates an infection hole. Work up fever. Keep PCP prophylaxis on the list. Do not skip HSV prophylaxis in profoundly lymphopenic patients when local protocols call for it.
Cefepime neurotoxicity versus nonconvulsive status epilepticus
Cefepime is a workhorse for healthcare ventriculitis and febrile neutropenia. It is also a GABA-A antagonist in toxic concentrations. Risk explodes when AKI is under-dosed (the patient still gets 2 g every 8 hours on a creatinine of 3.5 mg/dL without CRRT) or when the drug accumulates in an oliguric patient overnight. Clinical picture: progressive encephalopathy, aphasia, myoclonus, agitation, or coma, often without a convincing new fever source. EEG may show triphasic waves, stimulus-induced patterns, or true NCSE.
The exam move is not “add a third antiseizure drug and continue cefepime because the wound needs it.” The move is:
- EEG to characterize NCSE versus toxic encephalopathy
- Stop cefepime (or immediately reduce to a renal-adjusted dose if you have no alternative and the EEG is not seizing)
- Switch Gram-negative coverage to an agent the team can justify (ceftazidime, meropenem, aztreonam) based on allergies and microbiology
- Treat definite NCSE with the status pathway (benzodiazepine, then a second agent) while removing the toxin
Cefepime toxicity and NCSE can coexist: the drug lowers the seizure threshold. Dialysis can clear cefepime if the patient already needs RRT. Other beta-lactams (including high-dose penicillin and some carbapenems) can cause similar encephalopathy, but cefepime is the one written into neuro ICU items over and over.
Differentiate from other encephalopathies: ICANS after CAR-T, HSV, cryptococcus, cefepime, and nonconvulsive seizures can look identical at the door. Time course (drug started 3 days ago; CAR-T infusion 5 days ago; transplant month 2) plus EEG plus a focused PCR/antigen panel is how you avoid treating only one of them.
Dosing reminders that show up as options
- Load vancomycin and beta-lactams in sepsis even if GFR is low; then adjust.
- On CRRT, meropenem and cefepime are cleared—do not use once-daily ESRD meningitis underdosing while the filter runs (see 10.1).
- Acyclovir is dosed on ideal body weight to limit nephrotoxicity in obesity.
- Trimethoprim-sulfamethoxazole for PCP is dosed on the trimethoprim component (commonly 5 mg/kg IV every 6–8 hours in severe disease) and interacts with phenytoin and warfarin.
Exam traps
Piperacillin-tazobactam for EVD infection. Ceftriaxone 1 g daily for bacterial meningitis. Forgetting vancomycin until the pneumococcal MIC returns resistant. Forgetting ampicillin in a 72-year-old. Stopping acyclovir before the HSV PCR is sent. Blaming ICANS for every CAR-T encephalopathy without EEG or infection labs. Continuing full-dose cefepime through anuria while treating “new seizures” with three anticonvulsants. Calling cryptococcal antigen colonization in a steroid-dependent patient with high opening pressure.
An adult with community-onset fever, nuchal rigidity, and no healthcare hardware needs empiric antibiotics after blood cultures. Which regimen is most appropriate pending CSF results?
An oliguric patient on cefepime 2 g every 8 hours becomes mute and myoclonic. EEG shows electrographic seizures. What is the most important antimicrobial step?
A heart-transplant recipient on high-dose steroids has subacute headache, fever, and a very high LP opening pressure. Which opportunistic cluster should be tested immediately?
MRI suggests temporal-lobe encephalitis. CSF has arrived in the lab but HSV PCR will not result for 18 hours. Which antiviral plan is correct?